Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ.

Hurtado C, Safarova A, Smith M, Chung R, Bruyneel AAN, Gomez-Galeno J, Oswald F, Larson CJ, Cashman JR, Ruiz-Lozano P, Janiak P, Suzuki T, Mercola M.

Sci Rep. 2019 Jul 25;9(1):10811. doi: 10.1038/s41598-019-46948-5.

3.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes.

Huang HJ, Holub C, Rolzin P, Bilakovics J, Fanjul A, Satomi Y, Plonowski A, Larson CJ, Farrell PJ.

J Biol Chem. 2019 Jun 14;294(24):9567-9575. doi: 10.1074/jbc.RA118.007302. Epub 2019 May 2.

PMID:
31048375
4.

Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment.

Larson CJ.

Handb Exp Pharmacol. 2019;251:381-424. doi: 10.1007/164_2018_184.

PMID:
30689089
5.

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.

Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS.

Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2.

6.

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.

Riopel M, Seo JB, Bandyopadhyay GK, Li P, Wollam J, Chung H, Jung SR, Murphy A, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Koh DS, Larson CJ, Olefsky JM, Lee YS.

J Clin Invest. 2018 Apr 2;128(4):1458-1470. doi: 10.1172/JCI94330. Epub 2018 Mar 5.

7.

Time-dependent inhibition of PHD2.

Tcholakov I, Grimshaw CE, Shi L, Kiryanov A, Murphy ST, Larson CJ, Plonowski A, Ermolieff J.

Biosci Rep. 2017 Jun 30;37(3). pii: BSR20170275. doi: 10.1042/BSR20170275. Print 2017 Jun 30.

8.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003800. doi: 10.1161/CIRCHEARTFAILURE.116.003800.

9.

Developing New Treatments for Heart Failure: Focus on the Heart.

Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JG, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah HN, Butler J.

Circ Heart Fail. 2016 May;9(5). pii: e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727.

10.

Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease.

Hiatt WR, Armstrong EJ, Larson CJ, Brass EP.

Circ Res. 2015 Apr 24;116(9):1527-39. doi: 10.1161/CIRCRESAHA.116.303566. Review.

PMID:
25908726
11.

cGMP and Brown Adipose Tissue.

Hoffmann LS, Larson CJ, Pfeifer A.

Handb Exp Pharmacol. 2016;233:283-99. doi: 10.1007/164_2015_3. Review.

PMID:
25903412
12.

The persistent need for insulin sensitizers and other disease-modifying anti-diabetic drugs.

Larson CJ.

Expert Rev Endocrinol Metab. 2014 Jan;9(1):1-3. doi: 10.1586/17446651.2014.868304. Epub 2013 Dec 16.

PMID:
30743733
13.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P.

J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19.

PMID:
22497444
14.

BAROS results in 700 patients after laparoscopic Roux-en-Y gastric bypass with subset analysis of age, gender, and initial body mass index.

Al Harakeh AB, Larson CJ, Mathiason MA, Kallies KJ, Kothari SN.

Surg Obes Relat Dis. 2011 Jan-Feb;7(1):94-8. doi: 10.1016/j.soard.2010.09.020. Epub 2010 Oct 30.

PMID:
21126928
15.

Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Kucharski J, Lum C, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Urban J, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4819-24. doi: 10.1016/j.bmcl.2010.06.102.

PMID:
20663667
16.

KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst J, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Eur J Pharmacol. 2010 Apr 25;632(1-3):93-102. doi: 10.1016/j.ejphar.2010.01.011. Epub 2010 Feb 2.

PMID:
20132813
17.

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, Tall AR.

Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2054-60. doi: 10.1161/ATVBAHA.109.191320. Epub 2009 Oct 8.

18.

Number of weight loss attempts and maximum weight loss before Roux-en-Y laparoscopic gastric bypass surgery are not predictive of postoperative weight loss.

Jantz EJ, Larson CJ, Mathiason MA, Kallies KJ, Kothari SN.

Surg Obes Relat Dis. 2009 Mar-Apr;5(2):208-11. doi: 10.1016/j.soard.2008.08.015. Epub 2008 Aug 27.

PMID:
18996769
19.

'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5456-9. doi: 10.1016/j.bmcl.2008.09.028. Epub 2008 Sep 11.

PMID:
18835164
20.

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP.

J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097.

PMID:
18439103
21.

The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1772-7. doi: 10.1016/j.bmcl.2008.02.033. Epub 2008 Feb 16.

PMID:
18325768
22.

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.

Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J, Vajda E, Zhi L, Negro-Vilar A.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. Epub 2007 Nov 21.

23.

Refusals, denials, and patient choice: reasons prospective patients do not undergo bariatric surgery.

Sadhasivam S, Larson CJ, Lambert PJ, Mathiason MA, Kothari SN.

Surg Obes Relat Dis. 2007 Sep-Oct;3(5):531-5; discussion 535-6.

PMID:
17903773
24.

Length of stay and impact on readmission rates after laparoscopic gastric bypass.

Baker MT, Lara MD, Larson CJ, Lambert PJ, Mathiason MA, Kothari SN.

Surg Obes Relat Dis. 2006 Jul-Aug;2(4):435-9.

PMID:
16925375
25.

The effect of laparoscopic gastric bypass surgery on dyslipidemia in severely obese patients.

Zlabek JA, Grimm MS, Larson CJ, Mathiason MA, Lambert PJ, Kothari SN.

Surg Obes Relat Dis. 2005 Nov-Dec;1(6):537-42.

PMID:
16925287
26.

Travel distance, age, and sex as factors in follow-up visit compliance in the post-gastric bypass population.

Lara MD, Baker MT, Larson CJ, Mathiason MA, Lambert PJ, Kothari SN.

Surg Obes Relat Dis. 2005 Jan-Feb;1(1):17-21.

PMID:
16925196
27.

Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry.

Inglefield JR, Larson CJ, Gibson SJ, Lebrec H, Miller RL.

J Biomol Screen. 2006 Sep;11(6):575-85. Epub 2006 Jun 7.

PMID:
16760371
28.

Peptide binding identifies an ERalpha conformation that generates selective activity in multiple in vitro assays.

Larson CJ, Osburn DL, Schmitz K, Giampa L, Mong SM, Marschke K, Seidel HM, Rosen J, Negro-Vilar A.

J Biomol Screen. 2005 Sep;10(6):590-8. Epub 2005 Aug 15.

PMID:
16103420
29.

Apoptosis of circulating tumor cells in prostate cancer patients.

Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'hara SM, Russell T, Terstappen LW.

Cytometry A. 2004 Nov;62(1):46-53.

30.

Abnormal cervicovaginal smears due to endometriosis: a continuing problem.

Lundeen SJ, Horwitz CA, Larson CJ, Stanley MW.

Diagn Cytopathol. 2002 Jan;26(1):35-40.

PMID:
11782085
31.

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13920-5.

32.

Functional characterization of a purified, recombinant NF-kappaB/IkappaB complex.

Larson CJ, Li YW, Mercurio F, Müller R.

Biochem Biophys Res Commun. 1999 Jul 14;260(3):691-8.

PMID:
10403828
33.

Identification of oral mitis group streptococci by arbitrarily primed polymerase chain reaction.

Rudney JD, Larson CJ.

Oral Microbiol Immunol. 1999 Feb;14(1):33-42.

PMID:
10204478
34.

Freudian symbols on sexual and creative aspects of stories.

Larson CJ.

Psychol Rep. 1998 Jun;82(3 Pt 1):1059-72.

PMID:
9676517
35.

Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1 A resolution.

Cramer P, Larson CJ, Verdine GL, Müller CW.

EMBO J. 1997 Dec 1;16(23):7078-90.

36.

Saliva protein binding to streptococcal layers placed at different oral sites in 48 persons.

Rudney JD, Ji Z, Larson CJ.

J Dent Res. 1996 Oct;75(10):1789-97.

PMID:
8955674
37.

A DNA-bending protein interacts with an essential upstream regulatory element of the human embryonic beta-like globin gene.

Dyer MA, Naidoo R, Hayes RJ, Larson CJ, Verdine GL, Baron MH.

Mol Cell Biol. 1996 Mar;16(3):829-38.

38.

CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.

Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, Hiebert SW, Tenen DG.

Mol Cell Biol. 1996 Mar;16(3):1231-40.

39.
40.

Saliva protein binding to layers of oral streptococci in vitro and in vivo.

Rudney JD, Ji Z, Larson CJ, Liljemark WF, Hickey KL.

J Dent Res. 1995 Jun;74(6):1280-8.

PMID:
7543122
42.

Purification of the major histocompatibility complex class I transcription factor H2TF1. The full-length product of the nfkb2 gene.

Potter DA, Larson CJ, Eckes P, Schmid RM, Nabel GJ, Verdine GL, Sharp PA.

J Biol Chem. 1993 Sep 5;268(25):18882-90.

43.
44.

A high-capacity column for affinity purification of sequence-specific DNA-binding proteins.

Larson CJ, Verdine GL.

Nucleic Acids Res. 1992 Jul 11;20(13):3525. No abstract available.

45.

Human T-cell leukemia virus type I (HTLV-I) and blood transfusion.

Larson CJ, Taswell HF.

Mayo Clin Proc. 1988 Sep;63(9):869-75. Review.

PMID:
2900915
46.

Fatal acute dissection of the right hepatic artery after appendectomy.

Larson CJ, Geier GR Jr, Edwards WD.

Arch Pathol Lab Med. 1987 Mar;111(3):300-2.

PMID:
3827536

Supplemental Content

Loading ...
Support Center